Do hs-CRP, Lp-PLA2, and myeloperoxidase reflect different cardiovascular risk signals?

At age 52, these biomarkers can add different biological perspectives to cardiovascular risk assessment, but none directly “reads out” plaque status in an individual.

Clinical and interpretive evidence

• hs-CRP is the best-established marker here for systemic inflammation. It measures low circulating concentrations of hepatic CRP, an acute-phase protein induced chiefly by IL-6, with contributions from IL-1β and TNF-α. It is a downstream, nonspecific measure—not a measurement of cytokines or localization of inflammation to arteries. Acute illness, trauma, surgery, obesity, smoking, chronic inflammatory disease, medications, and liver disease can affect results. A value >10 mg/L should prompt consideration of an acute/transient cause and repeat testing after recovery; repeat values about two weeks apart help establish persistence.
• Lp-PLA₂ activity has a biologically credible but clinically imperfect relationship with vascular inflammation. Its association with coronary disease is modest and attenuates substantially after lipid adjustment; it has also lost associations with coronary calcification after adjustment for LDL-C, HDL-C, triglycerides, and CRP. It is not a validated standalone measure of plaque inflammation.
• MPO has prognostic relevance: elevated plasma MPO predicted major adverse cardiovascular events in stable coronary disease (adjusted HR 1.71), incident coronary heart disease in a community cohort (adjusted HR 1.50), and six-month death or myocardial infarction in acute coronary syndromes (adjusted HR 2.25).

Mechanistic context

• Lp-PLA₂ hydrolyzes oxidized phosphatidylcholine on LDL, generating lysophosphatidylcholine and oxidized fatty acids. These can promote leukocyte recruitment, endothelial dysfunction, apoptosis, necrotic-core formation, and vulnerability in macrophage-rich plaque.
• MPO released by neutrophils and macrophages generates hypochlorous acid, modifying LDL/HDL, impairing cholesterol efflux, promoting foam cells, endothelial injury, matrix damage, and matrix-metalloproteinase activation—pathways relevant to cap weakening and plaque disruption.

Bottom line

• hs-CRP reliably reflects systemic inflammatory burden; Lp-PLA₂ activity is a lipid-confounded surrogate for local plaque biology; and MPO is associated with oxidative vascular injury, plaque vulnerability, and cardiovascular events. Neither Lp-PLA₂ nor MPO blood testing alone establishes the presence or severity of vulnerable plaque.